Pharmacokinetics of Tenofovir and 3TC During Pregnancy

Pregnancy increased the apparent clearance of tenofovir and 3TC by 39% and 22%, respectively, but the clinical significance of this is unknown.

Tenofovir and 3TC are among the most frequently used antiretrovirals during pregnancy, but pharmacokinetic data in this setting are limited. Two new studies — one focused on each of the drugs — address this issue.

For the tenofovir study, researchers measured plasma drug levels in 46 HIV-infected women who were at various stages of pregnancy and 156 HIV-infected women who were not pregnant. All the women were taking standard 300-mg doses of tenofovir once daily; among the pregnant women, 85% were also receiving a protease inhibitor (PI), and 12% were receiving a nonnucleoside reverse transcriptase inhibitor (NNRTI). A total of 326 measurements were obtained, 1–29 hours after the last tenofovir dose.

Tenofovir clearance was found to decrease s…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Pharmacokinetics of Tenofovir and 3TC During Pregnancy

Topics

Reviewing Author